MARKET

PXMD

PXMD

PaxMedica, Inc.
NASDAQ
2.400
-0.050
-2.04%
After Hours: 2.430 +0.03 +1.25% 19:59 09/30 EDT
OPEN
2.400
PREV CLOSE
2.450
HIGH
2.850
LOW
2.250
VOLUME
617.33K
TURNOVER
0
52 WEEK HIGH
10.48
52 WEEK LOW
2.040
MARKET CAP
24.04M
P/E (TTM)
-30.1887
1D
5D
1M
3M
1Y
5Y
Barclays, Deutsche Bank, Equitrans Midstream among premarket losers' pack
Mind Medicine MNMD -43% on p...
Seekingalpha · 3d ago
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers
Benzinga · 4d ago
Nasdaq Turns Higher; Crude Oil Rises Over 2%
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Benzinga · 4d ago
VJET, MTP and EVAX among mid-day movers
Gainers: Avenue Therapeutics (ATXI) +165%. PaxMedi...
Seekingalpha · 4d ago
US Stocks Turn Lower; Dow Dips 175 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday.
Benzinga · 4d ago
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 4d ago
BRIEF-PaxMedica Provides Corporate Update After IPO
BRIEF-PaxMedica Provides Corporate Update After IPO
Reuters · 4d ago
PaxMedica, Provides Corporate Update After IPO; Appointment Of Stephen D. Sheldon As CFO
-PXMD Strengthened Executive Team with Recent Appointment of Stephen D. Sheldon As Chief Financial Officer- -Second Independent Director, Dr. John F. Coelho, Appointed to Board of Directors in May 2022- TARRYTOWN, NY,
Benzinga · 4d ago
More
About PXMD
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Its product candidates include PAX-101 and PAX-102. Its lead program, PAX-101, is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders, such as ME/CFS and Long COVID-19 Syndrome (LCS). It is also focused on developing PAX-101 for the treatment of East African Human-African Trypanosomiasis (HAT), which is caused by the parasite Trypanosome brucei rhodesiense. It is also focused on developing PAX-102, which is an intranasal formulation of suramin for neurologic indications.

Webull offers kinds of PaxMedica Inc stock information, including NASDAQ:PXMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PXMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PXMD stock methods without spending real money on the virtual paper trading platform.